Cargando…

Structural Determinants of Isoform Selectivity in PI3K Inhibitors

Phosphatidylinositol 3-kinases (PI3Ks) are important therapeutic targets for the treatment of cancer, thrombosis, and inflammatory and immune diseases. The four highly homologous Class I isoforms, PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ have unique, non-redundant physiological roles and as such, isoform selec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miller, Michelle S., Thompson, Philip E., Gabelli, Sandra B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468644/ https://www.ncbi.nlm.nih.gov/pubmed/30813656 http://dx.doi.org/10.3390/biom9030082

Ejemplares similares

Management of toxicity to isoform α-specific PI3K inhibitors
por: Nunnery, S E, et al.
Publicado: (2019)

Structural basis of nSH2 regulation and lipid binding in PI3Kα
por: Miller, Michelle S., et al.
Publicado: (2014)

PI3Kα Inhibitors That Inhibit Metastasis
por: Schmidt-Kittler, Oleg, et al.
Publicado: (2010)

Functional redundancy of PI3K isoforms in conventional T cells provides a selective Treg-targeting strategy through inhibition of PI3K-delta isoform
por: Ahmad, Shamim, et al.
Publicado: (2014)

Identification of ARUK2002821 as an isoform-selective PI5P4Kα inhibitor
por: Willems, Henriëtte M. G., et al.
Publicado: (2023)

IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer
por: Badarni, Mai, et al.
Publicado: (2021)

The role of PI3Kα isoform in cardioprotection
por: Rossello, Xavier, et al.
Publicado: (2017)

PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors
por: Lonetti, Annalisa, et al.
Publicado: (2015)

Selective Inhibition of PI3K Isoforms in Brain Tumors Suppresses Tumor Growth by Increasing Radiosensitivity
por: Seol, Mi Youn, et al.
Publicado: (2023)

Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas
por: Xie, Shaozhen, et al.
Publicado: (2020)

Efficacy of PI3K inhibitors in advanced breast cancer
por: Verret, B, et al.
Publicado: (2019)

Antigen receptor signalling: a distinctive role for the p110δ isoform of PI3K
por: Okkenhaug, Klaus, et al.
Publicado: (2007)

PI3K inhibitors in thrombosis and cardiovascular disease
por: Durrant, Tom N., et al.
Publicado: (2020)

The p110δ crystal structure uncovers mechanisms for selectivity and potency of novel PI3K inhibitors
por: Berndt, Alex, et al.
Publicado: (2010)

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors
por: Brandão, M, et al.
Publicado: (2019)

Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer
por: Weigelt, Britta, et al.
Publicado: (2012)

Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors
por: Rewcastle, Gordon W, et al.
Publicado: (2017)

Combining radiation with PI3K isoform-selective inhibitor administration increases radiosensitivity and suppresses tumor growth in non-small cell lung cancer
por: Seol, Mi Youn, et al.
Publicado: (2022)

Targeting Class I(A) PI3K Isoforms Selectively Impairs Cell Growth, Survival, and Migration in Glioblastoma
por: Höland, Katrin, et al.
Publicado: (2014)

Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3Kα-selective Inhibitors in Breast Cancer
por: Xu, Yi-chao, et al.
Publicado: (2017)

Development and safety of PI3K inhibitors in cancer
por: Yu, Miaomiao, et al.
Publicado: (2023)

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2013)

PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise
por: Bou Zeid, Naji, et al.
Publicado: (2023)

PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment
por: Piddock, R E, et al.
Publicado: (2017)

Isoform-Selective NFAT Inhibitor: Potential Usefulness and Development
por: Kitamura, Noriko, et al.
Publicado: (2021)

The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma
por: Piddock, Rachel E., et al.
Publicado: (2017)

Heterogeneity of Phosphatidylinositol-3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin Activation in Cancer: Is PI3K Isoform Specificity Important?
por: Cintas, Célia, et al.
Publicado: (2018)

Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer
por: Tankova, Tsvetalina, et al.
Publicado: (2022)

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
por: Mishra, Rosalin, et al.
Publicado: (2021)

The Isoform Selective Roles of PI3Ks in Dendritic Cell Biology and Function
por: Aksoy, Ezra, et al.
Publicado: (2018)

Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances
por: Liu, Xiaochuan, et al.
Publicado: (2016)

Selection Study for B+- -> (K-+ pi+- pi-+ pi+-)D K+- and B+- -> (K+ K- pi+ pi-)D K+-".
por: Hunt, P, et al.
Publicado: (2009)

Determination of the branching ratios $\Gamma(K_{L} \to 3\pi^{0}) / \Gamma(K_{L} \to \pi^{+}\pi^{-}\pi^{0})$ and $\Gamma(K_{L} \to 3\pi^{0}) / \Gamma(K_{L} \to \pi e\nu)$
por: Kreutz, A., et al.
Publicado: (1994)

IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer
por: Zorea, Jonatan, et al.
Publicado: (2018)

PTEN regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression
por: Miller, Karina, et al.
Publicado: (2023)

Thiazolidinedione-Based PI3Kα Inhibitors: An Analysis of Biochemical and Virtual Screening Methods
por: Pinson, Jo-Anne, et al.
Publicado: (2011)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Therapeutic Potency of PI3K Pharmacological Inhibitors of Gastrointestinal Cancer
por: Hashemzadeh, Kamelia, et al.
Publicado: (2019)

PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
por: Tarantelli, Chiara, et al.
Publicado: (2021)

Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy
por: Sirico, Marianna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cs87fjtc2on7t0askqln780mkf